Anti-Psychotic Drug Effective Against Chemo-Induced Nausea and Vomiting

According to an abstract that will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago, a familiar anti-psychotic drug called olanzapine (marketed as Zyprexa) is effective at reducing the nausea and vomiting which is a side effect of chemotherapy.

Rudolph Navari, MD, PhD, of Indiana University School of Medicine in South Bend, reported the abstract, noting that it was from a phase III clinical trial showing that olanzapine "significantly improved the control of breakthrough nausea and vomiting caused by chemotherapy."

Olanzapine controls nausea

This is said to be the first study to show that such nausea and vomiting can be controlled even when it occurs despite guideline-directed treatment meant to avoid it.

The study involved 80 cancer patients, with a wide variety of tumor types and chemotherapy regimens. Following chemotherapy dosing, the patients were randomly assigned to take olanzapine at 10 milligrams once a day for 3 days or metoclopramide (sold under many brand names) at 10 milligrams 3 times a day for 3 days.

Out of the 42 patients given olanzapine, 30 of them or 71 percent, did not vomit, compared to 13 of the 38 patients, or 32 percent, given metoclopramide.

Additionally, 28 patients, or 67 percent, in the olanzapine arm didn't even experience nausea, compared with nine,or 24 percent, in the metoclopramide patients.

The data will be presented in Chicago at the ASCO meeting in June.

Source: Medpage Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap